OKYO Pharma Limited
OKYO Pharma Limited (EMMLF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
emmlf · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
OKYO Pharma LimitedYou EMMLF | $23M | N/A | — | -$0.12 |
 American Hemp Ventures, Inc. AMHV | $16M | N/A | — | — |
 IBEX Technologies Inc. IBXNF | $25M | 6.80x | -13.7% | $0.16 |
 Kadimastem Ltd KMSTF | $10M | N/A | — | -$6.32 |
 Organicell Regenerative Medicine, Inc. OCEL | $20M | N/A | — | -$0.86 |
 OptiBiotix Health Plc OPBXF | $20M | 6.55x | -16.9% | $0.03 |
 PharmChem, Inc. PCHM | $22M | 10.30x | +30.6% | $0.30 |
Industry Average 3 peers with valid PE | — | 7.88x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for OKYO Pharma Limited (EMMLF) measures how much investors pay for each dollar of the company's trailing earnings. EMMLF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.12.
Frequently asked questions
EMMLF pe ratio · 6 questionsEMMLF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.01 and TTM EPS of -$0.12. Data sourced from Financial Modeling Prep via EMMLF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · OKYO Pharma Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08